Drug Trial Radar · NCT06292351
DMB-I in the Treatment of Alzheimer Type Dementia
Last checked: Nov 19, 2026Latest source record: Mar 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
133
Actual
Start
Dec 27, 2023
Primary completion
Jan 13, 2025
Study completion Jan 31, 2025
Sponsor
- Lead sponsor
- Bigespas LTDIndustry
- Sponsor type
- Industry
- First posted
- Mar 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of DMB-I for the treatment of patients with Alzheimer type dementia.
Conditions
- Alzheimer Disease
- Dementia of Alzheimer Type
Interventions
DMB-I (Dimebon)Drug
20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
PlaceboOther
20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in Alzheimer's Disease Assessment Scale score after 26 weeks of therapy (Visit 6) compared to baseline (Visit 0) in patients receiving the study drug or placeboTime frame: Baseline (Visit 0) and 26 weeks (Visit 6)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
State autonomous healthcare institution "Transregional Clinical Diagnostic Center"
Kazan', Russia
Federal State Budgetary Institution "Federal center for brain and neurotechnologies" of the Federal Medical and Biological Agency (FSBI "FCBN" of Russia's FMBA)
Moscow, Russia
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Moscow, Russia
State public healthcare institution Leningrad regional psychoneurologic dispensary
Roshchino, Russia
"Medical Center Nova Vita"
Rostov-on-Don, Russia
Saint Petersburg State budgetary healthcare institution "City Hospital № 40 of Kurortniy district"
Saint Petersburg, Russia
"Centre of evidence-based medicine" LLC
Yaroslavl, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.